Japan approves Kostaive (ARCT-154), a self-amplifying mRNA COVID-19 vaccine targeting Omicron, for distribution in October 2024.

Japan has approved Kostaive (ARCT-154), the first self-amplifying mRNA COVID-19 vaccine, developed by CSL and Arcturus Therapeutics, targeting the JN.1 Omicron strain. Set for distribution by Meiji Seika Pharma in the October 2024 vaccination campaign, this vaccine has shown superior immunogenicity compared to conventional mRNA boosters. Approval follows a health ministry panel's recommendation to update vaccines for Omicron subvariants.

September 13, 2024
5 Articles